Sutro Biopharma, Inc. (STRO) DCF Valuation
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Sutro Biopharma, Inc. (STRO) Bundle
Designed for accuracy, our (STRO) DCF Calculator enables you to evaluate Sutro Biopharma, Inc. valuation using real-world financial data while offering complete flexibility to modify all essential parameters for enhanced projections.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | 42.7 | 42.7 | 61.9 | 67.8 | 153.7 | 213.0 | 295.2 | 409.2 | 567.0 | 785.8 |
Revenue Growth, % | 0 | -0.03275927 | 44.84 | 9.52 | 126.84 | 38.58 | 38.58 | 38.58 | 38.58 | 38.58 |
EBITDA | -46.6 | -23.8 | -98.5 | -105.1 | -67.9 | -170.3 | -236.1 | -327.1 | -453.4 | -628.3 |
EBITDA, % | -109.08 | -55.6 | -159.22 | -155.03 | -44.18 | -79.96 | -79.96 | -79.96 | -79.96 | -79.96 |
Depreciation | 4.8 | 4.3 | 9.8 | 8.3 | 6.8 | 22.9 | 31.7 | 43.9 | 60.9 | 84.4 |
Depreciation, % | 11.18 | 10.06 | 15.79 | 12.23 | 4.43 | 10.74 | 10.74 | 10.74 | 10.74 | 10.74 |
EBIT | -51.4 | -28.1 | -108.3 | -113.4 | -74.7 | -176.5 | -244.6 | -339.0 | -469.8 | -651.1 |
EBIT, % | -120.26 | -65.66 | -175.01 | -167.26 | -48.61 | -82.85 | -82.85 | -82.85 | -82.85 | -82.85 |
Total Cash | 117.9 | 368.1 | 197.9 | 302.3 | 375.6 | 213.0 | 295.2 | 409.2 | 567.0 | 785.8 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | 6.3 | 5.6 | 12.5 | 7.1 | 36.1 | 34.9 | 48.3 | 67.0 | 92.8 | 128.6 |
Account Receivables, % | 14.74 | 13.01 | 20.13 | 10.51 | 23.47 | 16.37 | 16.37 | 16.37 | 16.37 | 16.37 |
Inventories | .0 | .0 | .0 | -11.7 | .0 | -7.3 | -10.2 | -14.1 | -19.5 | -27.1 |
Inventories, % | 0 | 0 | 0.000001616031 | -17.22 | 0 | -3.44 | -3.44 | -3.44 | -3.44 | -3.44 |
Accounts Payable | 5.6 | 5.5 | 6.0 | 4.8 | 9.4 | 20.9 | 28.9 | 40.1 | 55.5 | 77.0 |
Accounts Payable, % | 13.07 | 12.98 | 9.71 | 7.08 | 6.14 | 9.79 | 9.79 | 9.79 | 9.79 | 9.79 |
Capital Expenditure | -3.5 | -7.1 | -15.3 | -7.9 | -4.3 | -27.3 | -37.8 | -52.4 | -72.6 | -100.6 |
Capital Expenditure, % | -8.15 | -16.69 | -24.76 | -11.59 | -2.81 | -12.8 | -12.8 | -12.8 | -12.8 | -12.8 |
Tax Rate, % | -20.53 | -20.53 | -20.53 | -20.53 | -20.53 | -20.53 | -20.53 | -20.53 | -20.53 | -20.53 |
EBITAT | -51.4 | -31.6 | -111.5 | -115.8 | -90.1 | -176.5 | -244.6 | -339.0 | -469.8 | -651.1 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -50.8 | -33.7 | -123.5 | -99.6 | -123.6 | -160.9 | -253.3 | -351.0 | -486.4 | -674.1 |
WACC, % | 23.81 | 23.81 | 23.81 | 23.81 | 23.81 | 23.81 | 23.81 | 23.81 | 23.81 | 23.81 |
PV UFCF | ||||||||||
SUM PV UFCF | -919.0 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | -688 | |||||||||
Terminal Value | -3,153 | |||||||||
Present Terminal Value | -1,084 | |||||||||
Enterprise Value | -2,003 | |||||||||
Net Debt | -36 | |||||||||
Equity Value | -1,967 | |||||||||
Diluted Shares Outstanding, MM | 60 | |||||||||
Equity Value Per Share | -32.70 |
What You Will Get
- Pre-Filled Financial Model: Sutro Biopharma’s actual data enables precise DCF valuation.
- Full Forecast Control: Adjust revenue growth, margins, WACC, and other key drivers.
- Instant Calculations: Automatic updates ensure you see results as you make changes.
- Investor-Ready Template: A refined Excel file designed for professional-grade valuation.
- Customizable and Reusable: Tailored for flexibility, allowing repeated use for detailed forecasts.
Key Features
- Comprehensive Data: Sutro Biopharma’s historical financial statements and detailed forecasts.
- Customizable Parameters: Adjust WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Insights: View Sutro Biopharma’s intrinsic value recalculated instantly.
- Visual Data Representation: Interactive dashboard charts illustrate valuation results and essential metrics.
- Designed for Precision: A reliable tool tailored for analysts, investors, and finance professionals.
How It Works
- Download: Obtain the ready-to-use Excel file featuring Sutro Biopharma, Inc.'s (STRO) financial data.
- Customize: Modify projections, including revenue growth, EBITDA %, and WACC.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Generate various projections and compare results instantly.
- Make Decisions: Leverage the valuation outcomes to inform your investment strategy.
Why Choose This Calculator for Sutro Biopharma, Inc. (STRO)?
- Designed for Industry Experts: A sophisticated tool utilized by researchers, financial analysts, and biopharma executives.
- Comprehensive Data: Historical and projected financials for Sutro Biopharma preloaded for precision.
- Flexible Scenario Analysis: Easily simulate various forecasts and assumptions for informed decision-making.
- Insightful Outputs: Automatically computes intrinsic value, NPV, and other critical metrics.
- User-Friendly: Step-by-step guidance ensures a smooth and straightforward experience.
Who Should Use This Product?
- Professional Investors: Develop comprehensive and accurate valuation models for portfolio assessment related to Sutro Biopharma, Inc. (STRO).
- Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions within the company.
- Consultants and Advisors: Deliver precise valuation analyses and insights for clients interested in Sutro Biopharma, Inc. (STRO).
- Students and Educators: Leverage real-world data to enhance learning and practice in financial modeling.
- Biotech Enthusiasts: Gain insights into how biotechnology firms like Sutro Biopharma, Inc. (STRO) are valued in the investment landscape.
What the Template Contains
- Pre-Filled Data: Includes Sutro Biopharma, Inc.'s (STRO) historical financials and forecasts.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
- Key Financial Ratios: Analyze Sutro Biopharma, Inc.'s (STRO) profitability, efficiency, and leverage.
- Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
- Clear Dashboard: Charts and tables summarizing key valuation results.